Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: A multicenter confirmatory study

Article

Abstract: BACKGROUND AND PURPOSE - Plasma levels of cellular fibronectin (c-Fn) ≥3.6 μg/mL and of matrix metal

Palabras claves:

Biomarkers, blood-brain barrier, hemorrhage, Metalloproteinases, stroke, Thrombolytic therapy

Autores:

Arenillas J.F., Brea D., Castellanos M., Castillo J., Dávalos A., Millan M., Nombela F., Perez De La Ossa N., Serena J., Sobrino T., Vivancos J., Washington Stalin García Cuenta

Fuentes:

scopus